Vertex Pharmaceuticals has research and development sites, manufacturing facilities, headquarters and regional offices around the world.
18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor), to include use in infants with cystic fibrosis (CF) ages 6 mon...
BOSTON--(BUSINESS WIRE)--Oct. 27, 2022--Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today reported consolidated financial results for the third quarter endedSeptember 30, 2022and increased its full year 2022 revenue guidance. “The third quarter marked another period of strong performance in...
Vertex Pharmaceuticals (NASDAQ: VRTX) develops small molecule drugs for serious diseases. Use the CB Insights Platform to explore Vertex Pharmaceuticals's full profile.
(HCV) protease inhibitor, VX-950. Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia, and Vertex will retain exclusive commercial rights to VX-950 in North America. Tibotec Pharmaceuticals, Ltd., another Johnson & Johnson ...
Vertex Pharmaceuticals (Europe) Ltd. (the “UK Subsidiary”) has been in continuous existence since it was incorporated except where the failure to be in continuous existence could not reasonably be expected to have a Material Adverse Effect; and neither the Company nor any of its subsidiaries ...
Vertex Pharmaceuticals Incorporated Heather Nichols, 617-839-3607 heather_nichols@vrtx.com or Jeff Cournoyer, 978-935-8521 (mobile) 617-287-7377 (office) jcournoyer@umassp.edu or BostonPublic Schools Communications Office, 617-635-9265
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated(NASDAQ: VRTX) today announced the appointment ofJeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in t...
Application Number: 15/931944 Publication Date: 12/03/2020 Filing Date: 05/14/2020 Export Citation: Click for automatic bibliography generation Assignee: Vertex Pharmaceuticals (Europe) Limited International Classes: A61K31/47;A61K9/00;A61K9/16;A61K9/20;A61P11/00 ...
Attorney, Agent or Firm: Vertex Pharmaceuticals Incorporated/Finnegan Claims: 1. 1.-19. (canceled) 20. A compound represented by the following structural formula: 21. The compound of claim 20, wherein any atom not designated as deuterium is present at its natural isotopic abundance. 22. ...